Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Sells $388,864.07 in Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $37.01, for a total transaction of $388,864.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jeffrey Dierks also recently made the following trade(s):

• On Tuesday, October 29th, Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock. The stock was sold at an average price of $40.47, for a total value of $869,943.12.

Harmony Biosciences Stock Up 4.4 %

HRMY stock opened at $38.54 on Friday. The company has a 50 day moving average of $34.34 and a two-hundred day moving average of $34.78. The company has a market cap of $2.20 billion, a price-to-earnings ratio of 18.27, a PEG ratio of 0.49 and a beta of 0.78. Harmony Biosciences Holdings, Inc. has a 12-month low of $28.14 and a 12-month high of $41.61. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $186.00 million for the quarter, compared to the consensus estimate of $184.07 million. During the same period in the prior year, the business posted $0.63 earnings per share. Harmony Biosciences’s revenue for the quarter was up 16.0% compared to the same quarter last year. On average, equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HRMY has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Harmony Biosciences in a research report on Thursday. Needham & Company LLC reiterated a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a report on Monday. Mizuho boosted their price target on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, October 10th. Oppenheimer reaffirmed an “outperform” rating and issued a $59.00 price objective (up previously from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Finally, Cantor Fitzgerald boosted their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences presently has a consensus rating of “Buy” and an average target price of $55.00.

Institutional Investors Weigh In On Harmony Biosciences

Institutional investors have recently made changes to their positions in the company. ARS Investment Partners LLC bought a new position in Harmony Biosciences during the fourth quarter valued at approximately $841,000. Avanza Fonder AB bought a new position in shares of Harmony Biosciences during the 4th quarter valued at $145,000. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Harmony Biosciences by 38.3% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 75,072 shares of the company’s stock valued at $2,583,000 after purchasing an additional 20,798 shares in the last quarter. Mendota Financial Group LLC lifted its stake in shares of Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after purchasing an additional 965 shares during the last quarter. Finally, CWA Asset Management Group LLC boosted its holdings in Harmony Biosciences by 27.0% in the fourth quarter. CWA Asset Management Group LLC now owns 18,279 shares of the company’s stock worth $629,000 after purchasing an additional 3,883 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.